To assess the non-LDL-C-related dyslipidaemia risk of MI, 823 men aged 23 to 65 with a first MI were compared with 823 MI-free PROCAM controls matched for sex, age, smoking, DM, BP and LDL-C. Overall, the odds of MI in men with HDL-C < 1.15 mmol/L were 2.6 times those of men with HDL-C ≥ 1.15 mmol/L, and the odds of MI in men with triglycerides ≥ 1.71 mmol/L were 1.4 times those of men with lower triglycerides. If LDL-C was < 2.58 mmol/L, relative MI odds attributed to HDL-C < 1.15 mmol/L increased to 3.4, while relative odds attributed to triglycerides ≥ 1.71 mmol/L increased to 2.6; men in this LDL category with HDL-C < 1.15 mmol/L and/or triglycerides ≥ 1.71 mmol/L displayed an MI odds ratio of 5.0. MI risk associated with low HDL-C and/or high triglycerides is substantial, particularly if LDL-C is low.
Introduction
The progress that has been made in the last four decades in reducing cardiovascular risk is in danger of being undermined by the worldwide increase in overweight, metabolic syndrome and type 2 DM. Newer reports suggest that coronary heart disease mortality in developed countries may be on the increase, particularly in women and younger men. 1, 2 Current recommendations for the prevention of CHD stress the importance of intervention on a number of fronts to achieve target levels of LDL-C, BP and blood glucose. [3] [4] [5] [6] [7] [8] Despite the undoubted success of statin therapy, substantial risk of coronary artery disease remains even after achievement of optimal levels of LDL-C. Data from a recent metaanalysis 9,10 of 90,056 patients from 14 randomised trials, 18,686 of whom suffered from DM, showed that one in seven patients on statin treatment suffered a coronary event within five years of follow-up. Further reduction of LDL-C by use of the maximum permissible statin dosage is unlikely to be able to substantially lower this residual, largely non-LDL-mediated risk. 11, 12 Non-LDL-related lipid disorders are an important risk factor for atherosclerosis and accounted for half the attributable risk of acute MI in the INTERHEART study. 13 The combination of increased triglyceride and low HDL-C levels has been termed 'atherogenic dyslipidaemia' and is common in patients with type 2 DM, in sufferers from the metabolic syndrome, and in those with atherosclerosis. 14, 15 Increased triglycerides and low HDL-C, both independently [16] [17] [18] [19] and together, 20, 21 predict coronary events independently of LDL-C. In the PROCAM study, the combination of a triglyceride level of greater than or equal to 2.28 mmol/L, a total cholesterol to HDL-C quotient above five, In the present study, we examined the contribution of non LDL-C-related dyslipidaemia to coronary risk using a case-control approach in which 823 men who had survived an MI were matched with an equal number of well-characterised controls. The controls were male participants in the PROCAM study who were free of MI. We were especially interested in how strongly triglycerides and HDL-C were associated with MI in patients who had LDL-C levels below currently recommended therapeutic targets.
Patients and methods
We recruited 823 men aged 18 to 65 years with a first ST-elevation or non-ST-elevation acute MI from the Institute of Cardiovascular Research at the University of Witten/Herdecke, from the St Johannes Hospital in Dortmund (Prof. Heuer), from the Duisburg Heart Centre (Dr Heinrich), from the Mecklenburg-Western Pomeranian Heart and Diabetes Centre (Prof. Motz) and from the Wuppertal Heart Centre (Prof. Gülker). These four centres have large catchment areas and have a patient intake that is likely to be representative of the general German population. All participants gave written informed consent. The study was limited to men because of the much lower incidence of myocardial infarction in women in this age group, and because two-thirds of the participants in PROCAM are male. Acute MI was defined as the presence of each of the following three criteria: (1) chest pain or symptomatic equivalent lasting more than 20 min; (2) an ST-elevation of at least 0.1 mV in two adjoining ECG limb leads and/or an ST-elevation of at least 0.2 mV in two adjoining chest leads or a newly evident left bundle branch block or a fresh Q-wave lasting at least 0.03 sec; (3) creatinine kinase levels elevated to at least twice the upper normal limit or detection of either troponin T or troponin I.
All patients admitted to the above institutions with a suspected acute MI were assessed for inclusion. On confirmation of the diagnosis, the study doctor was informed, who then verified the inclusion criteria and obtained the patient's consent to take part. The analyses described in this report were performed on whole blood drawn at admission (i.e. within 12 h of the onset of pain). This was allowed to clot for 30 min at room temperature, after which time serum was separated by centrifugation for 10 min at 3,000 rpm and frozen at -20°C until analysis. All measurements were performed centrally at the laboratory of Münster University Hospital. Total cholesterol and triglycerides were measured using enzymatic assays, and HDL-C was measured using a precipitation method from Boehringer Mannheim on a Hitachi 737 autoanalyser. LDL-C was calculated using the Friedewald formula provided the triglyceride level was below 4.56 mmol/L. 25 Lp(a) was not measured.
The patients were matched to an equal number of controls from the PROCAM study. PROCAM is one of the largest prospective epidemiological studies of coronary heart disease risk factors worldwide. 26 Between 1978 and 2007, 50,000 employees (two-thirds male, one-third female) aged between 20 and 65 years at recruitment were recruited from more than 50 large companies and public authorities in the city of Münster and environs. Details of the study are reported elsewhere. 27 Examination at study entry included standardised case history, measurements of BP, height and weight, a resting ECG and collection of blood samples after a 12-h fast for determination of more than 20 laboratory parameters. Total cholesterol, triglycerides, HDL-C and LDL-C were measured in the PROCAM controls in the same way as in the MI patients. Participation was voluntary, and on average 60% of those eligible took part. Persons with a history of angina pectoris (based on the Rose questionnaire 28 ), MI (self-reported or ECG changes) or stroke (selfreported) were excluded from recruitment.
Criteria for matching cases and controls
MI survivors were matched for smoking status, presence of type 2 DM (diagnosis already made or fasting plasma glucose above 125 mg/dL), BP category (the BP categories were as follows: systolic below 140 mmHg and diastolic below 90 mmHg; systolic between 140 and 160 mmHg and/or diastolic between 90 and 95 mmHg; systolic above 160 mmHg and/or diastolic above 95 mmHg; an additional category of systolic below 130 mmHg and diastolic below 85 mmHg was established for persons with DM), LDL-C category (the LDL-C categories were as follows: below 2.58 mmol/L, between 2.58 and 3.35 mmol/L, between 3.36 and 4.12 mmol/L, and greater than or equal to 4.13 mmol/L) and age at entry into PROCAM (time at which blood tests were performed). Because of lack of adequate information from the MI survivors, matching for family history was not performed.
If more than one PROCAM participant fulfilled all the above matching criteria, the person with the closest LDL-C concentration to the MI survivor was chosen as a control. If no-one in PROCAM fulfilled the criteria, then men in PROCAM whose age differed by no more than one year from the MI survivor were considered. If a matching person in PROCAM could still not be found, then the possible age difference was extended in steps of one year until a match was obtained. The maximum age difference necessary to find a match was three years. Of the 823 matched pairs, the age difference between MI survivor and PROCAM control was no years in 515 pairs, one year in 200 pairs, two years in 77 pairs and three years in 31 pairs.
Calculation of OR
As this was a case-control study, the effects of low HDL-C and high triglycerides on MI risk were calculated as the ratio of the odds in the MI patients and controls. The odds of an HDL concentration below a particular cutoff, for example, were calculated by dividing the number of men with an HDL-C level below that cutoff by the number of men with an HDL-C level equal to or above the cutoff. The OR of MI below that HDL cutoff was then calculated by dividing these HDL cutoff odds in the MI cases by the HDL cutoff odds in the controls. For small risks such as the absolute MI risk in men with low HDL-C or high triglycerides as defined in the present study, OR closely approximates to relative risk. 29 
Results
The main characteristics of the MI survivor and PROCAM control groups are shown in table 1. As expected, there were no differences between the MI survivors and controls for the matching criteria of age, smoking status, presence of type 2 DM and BP. However, significant differences existed for HDL-C, which was 14% lower in the MI survivors, triglycerides (12% higher in MI survivors) and body mass index (4% higher in MI survivors). In addition, 36% of MI survivors had a sibling or parent who had suffered an MI before age 60, in contrast to 25% of the matched controls. The mean calculated 10-year risk of MI using the latest (Weibull function-based) PROCAM algorithm 30 was 14.4% in MI survivors and 11.5% among controls.
In order to determine whether levels of non-LDL lipids varied with LDL-C levels, we assessed the levels of HDL-C and triglycerides at different levels of LDL-C (table 2). In the MI survivors, triglycerides were highest in the lowest LDL category (less than 2.58 mmol/L, p for trend across the different LDL levels < 0.001), while HDL-C did not differ significantly between the different LDL categories. In the controls, by contrast, triglycerides were lowest (p for trend < 0.001), while HDL-C was highest, at the lowest level of LDL-C (p for trend 0.022).
Next, the prevalence of various degrees of high triglycerides and low HDL-C levels was examined in MI survivors and controls (table 3) . Even a slightly depressed HDL-C level of less than 1.15 mmol/L was associated with a 2.6fold increase in the odds of MI. This level of HDL-C was seen in 31% of the control population and 53% of the MI cases. HDL-C levels below 0.09 mmol/L were associated with a 3.2-fold increase in the odds for MI and were found in only 6% of controls, but in 17% of MI survivors. Similarly, triglyceride levels of at least 2.28 mg/dL were associated with a 1.8-fold increase in the odds for MI compared with those having a triglyceride level of less than 2.28 mg/dL, and were seen in 14% of controls and in 22% of MI survivors.
We further asked whether the increase in the odds ratio for MI associated with low HDL-C and high triglyceride levels varied according to the level of LDL-C (table 3) . HDL-C levels below 1.15 mmol/L and triglycerides equal to or above 1.71 mmol/L were more common in MI survivors than in controls at all levels of LDL-C (and at all levels of HDL-C and triglyceride). Moreover, in the MI survivors, the prevalence of these dyslipidaemias increased in those men with lower levels of LDL, a phenomenon that was not seen in the controls. In addition, the odds ratio for MI associated with HDL-C levels below 1.15 mg/dL and all levels of high triglycerides increased in men with lower levels of LDL-C. This phenomenon was not seen for the smaller groups of men with HDL-C levels below 1.05 mmol/L or below 0.09 mmol/L. When low HDL-C and high triglyceride levels were assessed together (table 4), the greatest OR for MI (2.7fold) was observed in men with triglycerides of at least 2.28 mmol/L and/or HDL-C levels below 1.05 mmol/L. This 'and/or' combination was seen in nearly twice as many MI survivors (46%) as controls (24%). The relative risk associated with the combination of low HDL-C and high triglycerides was not significantly greater than that seen in men with only one lipid abnormality (increase in OR 1.2, 95% confidence interval 0.9-1.6).
The subgroup of men with triglycerides of at least 1.71 mmol/L and/or HDL-C levels below 1.15 mmol/L was selected for further analysis. This subgroup was chosen in order to achieve sufficient numbers of cases and controls and therefore to allow more stable estimates of the OR. When this combination was examined in subgroups of men with different LDL-C levels, the effect on the OR for MI was striking (table 5). Whereas in men with high LDL-C levels of greater than or equal to 4.13 mmol/L the presence of either or both dyslipidaemias was associated with a twofold increase in the OR for MI, this OR increased to fivefold in men with LDL-C levels below 2.58 mmol/L.
Discussion
This case-control study has two main findings. The first and most important is that dyslipidaemia (HDL-C below 1.15 mmol/L and/or triglycerides greater than or equal to 1.71 mmol/L) is associated with the greatest increase in relative risk (calculated as the OR) of MI in persons with low levels of LDL-C (less than 2.58 mmol/L), i.e. in persons in whom LDL-C is unlikely to be making a large contribution to cardiovascular risk. This effect was also seen for triglyceride levels above or equal to 2.28 mmol/L (table 3) . The failure to see an increase in MI risk at low LDL-C levels in men with HDL levels below 1.05 mmol/L or 0.09 mmol/L is most likely a reflection of the small sample sizes in these subgroups. The second main finding is that, once other conventional MI risk factors (age, smoking status, presence of diabetes, total cholesterol and LDL-C, BP) are accounted for, low HDL-C makes a greater contribution to MI risk than do high triglycerides (table 3) . Taken together, therefore, our data show that the residual cardiovascular risk attached to combined dyslipidaemia is substantial, particularly in persons with low levels of LDL-C.
A potential source of bias in our results is the fact that our cases were all-comers, selected only on the basis of having survived an acute MI, while the controls were drawn from the working population, which is in aggregate healthier and enjoys a higher social status than the population at large (healthy worker effect). The effect of such a bias would have been to increase the level of other risk factors (e.g. low social status, low income, unemployment, poor nutrition, physical inactivity, obesity) in the MI group compared with the controls, and thus to a dilution of the effects of conventional risk factors such as lipids. For this reason, our findings are, if anything, strengthened by the possible existence of a healthy worker effect in this study. Moreover, much of the coronary risk associated with low social status A second potential source of bias is that, in the MI survivors, triglycerides (and therefore, indirectly, LDL-C) were measured on admission without reference to the fasting state, whereas the PROCAM controls were fasting when blood was drawn. This bias would be expected -all else being equal -to lead to higher aggregate triglyceride levels (and lower LDL-C levels) in the MI cases than in the controls. One of the criteria used for matching in the present study was the LDL-C level, and this bias would have led to underestimation of the underlying LDL-C level in the case members of the matching pairs, an effect which would have tended to dilute the effects of non-LDL-related lipids on MI risk. At the same time, there would have been overestimation of the underlying triglyceride level in the case in each matching pair, which might have led to overestimation of the relative odds attributable to this lipid. It is not possible to say which of these two opposing biases is the more dominant, so that some element of residual confounding may remain and must be borne in mind when interpreting our results. The same applies to confounding due to lack of matching for pharmacological treatment. Firstly, it must be borne in mind that the design of our investigation and other similar studies precludes such matching, since in most cases first MI develops unexpectedly. Having said that, in one study in Germany, only 9% of patients suffering an MI (in 80% of cases, a first MI) were taking lipid-lowering medication, 31 while fewer than 5% of the participants in PROCAM are known to be receiving lipid-lowering therapy, so any confounding due to lack of matching for relevant drugs is likely to have been small in extent.
The combination of high triglycerides and low HDL-C, often with elevated levels of apolipoprotein B and non-HDL-C, has been termed 'atherogenic dyslipidaemia'. 32 This form of dyslipidaemia is prevalent in patients with type 2 DM, metabolic syndrome and atherosclerosis 14, 15 and is associated with atherosclerosis of large blood vessels, 30 with microvascular disease, 33 with a proinflammatory state, 34, 35 and with activation of the coagulation cascade and suppression of fibrinolysis. [36] [37] [38] [39] In trials of pravastatin, 24 as well as in the more intensive Treatment to New Targets 12 and Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT/TIMI-22) 11 trials, low HDL-C levels and raised triglyceride levels were predictive of coronary events in patients with low levels of LDL-C, supporting the observational data seen in our casecontrol study.
In apportioning risk in patients with low LDL-C in our study, the greatest increase in odds of MI was associated with low HDL-C levels (table 3) . The combination of low HDL and high triglycerides was not associated with a greater increase in OR than either alone (table 4), i.e. the OR of MI associated with a low HDL-C in a patient with low LDL-C was not additionally increased if triglycerides were also increased.
As Sacks et al. have commented previously, 24 the finding of increased relative triglyceride-and HDL-associated risk at low LDL-C levels may indicate that raising HDL and lowering triglycerides have greater potential for clinical benefit when LDL-C is low.
Current treatment of dyslipidaemia focuses on the use of statins to lower LDL-C, a strategy that has proved extremely successful. However, this treatment is approaching the limits of its effectiveness. In the Treatment to New Targets (TNT) 12 and Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trials, 40 substantial residual risk of coronary disease remained despite achievement of LDL-C levels well below the current high-risk target of 2.58 mmol/L. Efforts to reduce this non-LDL-mediated residual atherogenic risk have focused on both lifestyle changes and pharmacological treatment, chiefly by means of fibrates and niacin. The major effect of fibrates is a decrease in triglycerides of about 25%. However, despite much study, a definitive risk-benefit analysis of this form of treatment is not possible at the present time. 32 Niacin is the most potent agent currently available for increasing HDL-C. The Coronary Drug Project is the only randomised controlled coronary prevention trial of niacin as a sole agent. In men with MI in this trial, niacin produced a significant (p < 0.05) drop in coronary deaths and non-fatal MI within the five-year study period. 41 Moreover, with a follow-up period of 15 years, in the niacin group total mortality was reduced by 11% (p = 0.0004) and coronary mortality by 12% (p = 0.005). 42 However, as with fibrates, a final judgement on the benefits of niacin is not possible at the present time. Three major trials are currently in progress to clarify these issues. [43] [44] [45] 
